Floatz logo

sys6010

Recurrent or Metastatic Breast Cancer

CSPC Megalith Biopharmaceutical Co.,Ltd.Phase 3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

890 Active assets in the Recurrent or Metastatic Breast Cancer cohort.

Asset / SponsorPhaseRating
Lapatinib
University of New Mexico
Phase 3BBB
Darolutamide
Vandana Abramson
Phase 2BBB
Trastuzumab Duocarmazine
Byondis B.V.
Phase 3BB
Loratadine
Noha Mansour
Phase 2BB
VITAMIN D
University of Illinois at Chicago
Phase 4BB

View all 50 →

Same molecule, other indications

sys6010 is also rated in:

non-small cell lung carcinomaDormant
B
Indicative ·
58 / 100
View asset →
breast cancerDormant
CCC
Indicative ·
54 / 100
View asset →
small cell lung carcinomaDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →